尼拉帕尼（Niraparib，商品名Zejula^TM）是聚腺苷二磷酸-核糖聚合酶（PARP）的口服小分子抑制劑，PARP抑制是治療由DNA修復(fù)基因（如BRCA1和BRCA2）特異性畸變引起的DNA修復(fù)機(jī)制缺陷的癌癥的有效策略。尼拉帕尼于2017年3月在美國獲批，維持治療復(fù)發(fā)性上皮性卵巢癌、輸卵管癌、原發(fā)性腹膜癌的成年患者，這些患者對鉑類化療有完全或部分反應(yīng)，推薦劑量為口服300 mg/d，直到疾病發(fā)生惡化或產(chǎn)生無法接受的不良反應(yīng)。臨床研究結(jié)果表明該藥可以延長患者的無惡化生存期，為治療卵巢癌提供了有效和可靠的治療手段。

Niraparib is an oral small molecule inhibitor of poly(ADP-ribose) polymerase (PARP). PARP inhibition is an effective strategy for the treatment of cancers with deficienty in DNA repair mechanisms induced by specific aberrations of DNA repair genes (eg. BRCA1 and BRCA2). Niraparib was approved in the United States in March 2017 for maintenance treatment of adult patients with recurrent epithelial ovarian cancer, fallopian tubes cancer, and primary peritoneal cancer. These patients have a complete or partial response to platinum-based chemotherapy. The recommended dose is 300 mg/d until the diseases worsen or produce unacceptable adverse reactions. The results of clinical studies show that Niraparib can prolong the patient's non-progressive survival and provide an effective and reliable treatment for ovarian cancer.